الفهرس 
Title : Effect of Nanoparticles of Spiramycin on Experimental Toxoplasmosis
ContentsOnly 14 pages are availabe for public view
 |  | from | 209 |  |  |
| | | from | 209 | | |
Abstract
Spiramycin is a relatively safe antibiotic. Due to its concentration in the placenta and ability to adhere to tissues, it is utilized to prevent the transmission of T.gondii from the mother to the fetus (Dubey, 2005).
Spiramycin’s anti-Toxoplasmic action was tested in mouse models, however, the results were only somewhat positive. Despite some dependent survival extensions, it was unable to prevent mice from dying (Grujic et al., 2005).
Spiramycin’s oral bioavailability ranges from 10 to 69 percent, with an incomplete absorption rate of 33 to 39 percent (Reynolds, 1993). Due to Spiramycin’s high pKa (7.9), which indicates a significant level of ionization in the acidic stomach, the rate of absorption is slow. Spiramycin also fails to cross the blood-brain barrier